G Remuzzi

Summary

Affiliation: Istituto di Ricerche Farmacologiche Mario Negri
Country: Italy

Publications

  1. ncbi Rituximab for idiopathic membranous nephropathy: who can benefit?
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Clin J Am Soc Nephrol 1:738-48. 2006
  2. ncbi Chronic allograft nephropathy. A multiple approach to target nonimmunological factors
    Piero Ruggenenti
    Department of Medicine and Transplantation, Ospedali Riuniti, Azienda Ospedaliera, Italy
    Contrib Nephrol 146:87-94. 2005
  3. ncbi Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level
    Borislav D Dimitrov
    Department of Renal Medicine, Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica BG, Italy
    Kidney Int 63:1924-33. 2003
  4. ncbi Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 3:1652-9. 2008
  5. ncbi Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review
    Annalisa Perna
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Kidney Dis 44:385-401. 2004
  6. ncbi Conflict of interest as seen from a researcher's perspective
    Arrigo Schieppati
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Sci Eng Ethics 8:337-42. 2002
  7. ncbi [Thrombotic microangiopathy]
    C Chiurchiu
    Clinical Research Center for Rare Diseases, Aldo e Cele Dacc, Villa Camozzi, Ranica, Bergamo, Italy
    Nefrologia 23:13-20. 2003
  8. ncbi Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No
    G Remuzzi
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories and, Division of Nerphrology and Dialysis, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Italy
    J Thromb Haemost 1:632-4. 2003
  9. ncbi Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases, Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 31:1629-34. 2008
  10. ncbi Role of remission clinics in the longitudinal treatment of CKD
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 19:1213-24. 2008

Detail Information

Publications147 found, 100 shown here

  1. ncbi Rituximab for idiopathic membranous nephropathy: who can benefit?
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Clin J Am Soc Nephrol 1:738-48. 2006
    ....
  2. ncbi Chronic allograft nephropathy. A multiple approach to target nonimmunological factors
    Piero Ruggenenti
    Department of Medicine and Transplantation, Ospedali Riuniti, Azienda Ospedaliera, Italy
    Contrib Nephrol 146:87-94. 2005
  3. ncbi Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level
    Borislav D Dimitrov
    Department of Renal Medicine, Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica BG, Italy
    Kidney Int 63:1924-33. 2003
    ..Predicting outcomes such as end-stage renal disease (ESRD) by integration and better utilization at individual level of epidemiologic data may facilitate clinical decision-making processes...
  4. ncbi Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 3:1652-9. 2008
    ..Whether this is associated with kidney function restoration and regression of the glomerular pathology was evaluated...
  5. ncbi Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review
    Annalisa Perna
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Kidney Dis 44:385-401. 2004
    ..This study aims to assess whether immunosuppression is beneficial in the treatment of idiopathic membranous nephropathy (IMN)...
  6. ncbi Conflict of interest as seen from a researcher's perspective
    Arrigo Schieppati
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Sci Eng Ethics 8:337-42. 2002
    ..Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research...
  7. ncbi [Thrombotic microangiopathy]
    C Chiurchiu
    Clinical Research Center for Rare Diseases, Aldo e Cele Dacc, Villa Camozzi, Ranica, Bergamo, Italy
    Nefrologia 23:13-20. 2003
  8. ncbi Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No
    G Remuzzi
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories and, Division of Nerphrology and Dialysis, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Italy
    J Thromb Haemost 1:632-4. 2003
  9. ncbi Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases, Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 31:1629-34. 2008
    ..We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH)...
  10. ncbi Role of remission clinics in the longitudinal treatment of CKD
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 19:1213-24. 2008
    ....
  11. ncbi Retarding progression of chronic renal disease: the neglected issue of residual proteinuria
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research and Unit of Nephrology, Ospedali Riuniti, Azienda Ospedaliera, Bergamo, Italy
    Kidney Int 63:2254-61. 2003
    ..Findings that early changes in proteinuria independently predict long-term glomular filtration rate (GFR) decline (Delta GFR) would highlight proteinuria as a major determinant of progression in chronic renal disease...
  12. ncbi Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection
    Carlos Chiurchiu
    Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Villa Camozzi Ranica, Bergamo, Italy
    Am J Kidney Dis 41:E4. 2003
    ..Cases of D- HUS need to be carefully examined for foci other than the gastrointestinal tract, and patients with E coli bacteremia should receive early antibiotic treatment as would any patient with sepsis...
  13. ncbi Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 26:502-9. 2003
    ..To assess whether the insulin analog lispro may antagonize the renal effects of IGF-1, a mediator of glomerular hyperfiltration involved in the progression of diabetic and nondiabetic chronic nephropathies...
  14. ncbi Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 17:3472-81. 2006
    ..As compared with trandolapril, Veratran may help with achievement of target BP with less need for concomitant antihypertensive medications...
  15. ncbi Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute, Bergamo, Italy
    Circulation 107:586-92. 2003
    ..Dyslipidemia frequently complicates chronic nephropathies and increases the risk of renal and cardiovascular events. This might be ameliorated by drugs, such as angiotensin-converting enzyme inhibitors, which effectively reduce proteinuria...
  16. ncbi Preventing microalbuminuria in type 2 diabetes
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi, Ranica, Bergamo, Italy
    N Engl J Med 351:1941-51. 2004
    ....
  17. ncbi Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft
    M Noris
    Department of Immunology and Clinics of Organ Transplantation Ospedali Riuniti Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 12:1937-46. 2001
    ..Together, these findings provide the basis to prevent chronic injury and progressive dysfunction after renal transplantation...
  18. ncbi Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation
    M Noris
    Department of Immunology and Clinics of Organ Transplantation, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 12:2815-26. 2001
    ..This effect appears to occur through migration of donor MHCII(+) cells in the host thymus...
  19. ncbi Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis
    C Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Kidney Dis 31:453-63. 1998
    ..These findings may be relevant for future strategies in the treatment of human mesangioproliferative glomerulonephritis...
  20. ncbi Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy
    C Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Exp Nephrol 6:121-31. 1998
    ....
  21. ncbi Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism
    A Remuzzi
    Department of Kidney Research, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Exp Nephrol 6:28-38. 1998
    ..Prevention of renal functional and structural abnormalities by antagonism of AII activity in diabetic MWF rats suggests a pathogenetic role for angiotensin in inducing the renal disease in these animals...
  22. ncbi Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
    P Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò Villa Camozzi, Ranica
    Am J Kidney Dis 35:1155-65. 2000
    ..During the study period, those with proteinuria less than 2 g/24 h of protein, type 2 diabetes, or polycystic kidney disease did not benefit by treatment to an appreciable extent...
  23. ncbi Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)
    P Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò Villa Camozzi, Ranica, Italy
    J Am Soc Nephrol 11:88-96. 2000
    ..This information may help to guide therapeutic interventions in clinical practice and to interpret the results of prospective trials in chronic renal disease...
  24. ncbi Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis
    C Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 60:653-63. 2001
    ..We also examined the combination of MMF with a selective cyclooxygenase-2 (COX-2) inhibitor, DFU, based on previous findings of excessive renal production of COX-2-derived thromboxane A2 (TXA2) in lupus nephritis...
  25. ncbi Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model
    A Benigni
    Mario Negri Institute for Pharmacological Research, Unit of Nephrology and Dialysis, Bergamo, Italy
    Am J Kidney Dis 33:746-53. 1999
    ....
  26. ncbi Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Villa Camozzi, Ranica, Italy
    J Hypertens 29:207-16. 2011
    ..To address whether nondihydropyridine calcium-channel blocker added-on angiotensin-converting-enzyme inhibitor therapy ameliorates albuminuria and cardiovascular outcomes in type 2 diabetes patients...
  27. ncbi Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Bergamo, Italy
    Hypertension 58:776-83. 2011
    ..In hypertensive type 2 diabetic patients, combined manidipine and delapril therapy failed to slow GFR decline but safely ameliorated cardiovascular disease, retinopathy, and neuropathy and stabilized insulin sensitivity...
  28. ncbi Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion
    R A Cavinato
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi, Azienda Ospedaliera, Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 71:1132-41. 2007
    ..The healed graft is a source of donor antigens, which led to early selection of Treg. In the late phase, tolerance is maintained by appearance of Treg in LN...
  29. ncbi In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia
    P Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò Villa Camozzi, Ranica, Italy
    J Am Soc Nephrol 10:997-1006. 1999
    ..The present results offer evidence that in chronic nephropathies, the tendency of GFR to decline with time can be effectively halted, even in patients with remarkably severe disease...
  30. ncbi Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease
    M Abbate
    Mario Negri Institute for Pharmacological Research, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Italy
    J Am Soc Nephrol 10:804-13. 1999
    ....
  31. ncbi Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purp
    M Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Italy
    J Am Soc Nephrol 10:281-93. 1999
    ..05). Reduced C3 clusters in familial HUS and TTP is likely related to a genetically determined deficiency in factor H and may predispose to the disease. Its demonstration may help identify subjects at risk in affected families...
  32. ncbi Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 5:1928-38. 2010
    ....
  33. ncbi Time to abandon microalbuminuria?
    P Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Kidney Int 70:1214-22. 2006
    ..Future studies are needed to identify levels of albuminuria below which therapy is no longer beneficial...
  34. ncbi Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue
    C Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Lab Invest 64:16-20. 1991
    ....
  35. ncbi Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist
    A Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Pathol 159:1743-50. 2001
    ..Agents that only reduced hypertension but not proteinuria do not affect tubular behavior...
  36. ncbi Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension
    M Noris
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Kidney Dis 32:115-24. 1998
    ..Weight and blood volume loss and sodium balance were similar in AD, BD, and AFB. These data were consistent with the possibility that NO and cytokines, released in excessive amounts during AD, may contribute to hemodynamic instability...
  37. ncbi Selective dietary restriction of protein and calorie intakes prevents spontaneous proteinuria in male MWF rats
    D Macconi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Exp Nephrol 5:404-13. 1997
    ..We compared the effects of selective protein and calorie restriction on glomerular hemodynamics and proteinuria in a model of spontaneous glomerular injury in the rat...
  38. ncbi ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy
    A Remuzzi
    Unit of Nephrology, Dialysis Ospedali Riuniti di Bergamo, Bergamo, Italy
    Am J Kidney Dis 34:626-32. 1999
    ..Thus, in proteinuric MWF rats, late-onset ACE inhibition normalized blood pressure, effectively and progressively restored high protein excretion rate toward normal values, and arrested progression of tissue damage...
  39. ncbi Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis
    A Benigni
    Mario Negri Institute Bergamo, Italy Ospedali Riuniti di Bergamo, Azienda Ospedaliera, Bergamo, Italy
    J Am Soc Nephrol 12:941-8. 2001
    ....
  40. ncbi Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation
    D Cattaneo
    Department of Immunology and Transplantation, Ospedali Riuniti Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Transplant 5:2937-44. 2005
    ..CsA, but not SRL, inhibits MPA enterohepatic recirculation, reducing MPA daily exposure...
  41. ncbi Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note
    F Gaspari
    Department of Transplant Immunology and Innovative Antirejection Therapies, Ospedali Riuniti Bergamo, Mario Negri Institute for Pharmacological Research, Italy
    Kidney Int 54:2146-50. 1998
    ..The new microemulsion formulation of cyclosporine (CsA-ME) displays more consistent pharmacokinetic properties than the original formulation and may allow successful implementation of an abbreviated area-under-the-curve (AUC) strategy...
  42. ncbi Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion
    P Ruggenenti
    Mario Negri Institute for Pharmacological Research, , Villa Camozzi, Ranica, and Unit of Nephrology, Ospedali Riuniti, Azienda Ospedaliera, Bergamo, Italy
    Nephron 88:254-9. 2001
    ..This approach should be formally explored in prospective studies...
  43. ncbi Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression
    A Benigni
    Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Italy
    Curr Opin Nephrol Hypertens 10:1-6. 2001
    ..Trials are needed to explore this potential area of clinical interest...
  44. ncbi Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura
    P Ruggenenti
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 60:831-46. 2001
    ..Plasma infusion or exchange is the only treatment of proven efficacy. Bilateral nephrectomy and splenectomy may serve as rescue therapies in very selected cases of plasma resistant HUS or recurrent TTP, respectively...
  45. ncbi Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes
    P Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Centre for Rare Diseases, Bergamo, Italy
    BMJ 316:504-9. 1998
    ....
  46. ncbi Progression, remission, regression of chronic renal diseases
    P Ruggenenti
    , Ospedali Riuniti di Bergamo, 24125, Bergamo, Italy
    Lancet 357:1601-8. 2001
    ..Experimental and clinical data lend support to the notion that less dialysis (and maybe none for some patients) is at least possible...
  47. ncbi Early experience with dual kidney transplantation in adults using expanded donor criteria. Double Kidney Transplant Group (DKG)
    G Remuzzi
    Ospedali Riuniti di Bergamo, Clinical Research Center Aldo e Cele Daccò, Bergamo, Italy
    J Am Soc Nephrol 10:2591-8. 1999
    ....
  48. ncbi Kidney failure stabilizes after an increase over 2 decades
    Paolo Cravedi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Ren Care 33:100-4. 2007
    ..Early intervention may be important to maximize renoprotection, especially in diabetics...
  49. ncbi Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Lancet 365:939-46. 2005
    ....
  50. ncbi Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice
    C Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 8:720-9. 1997
    ..These data suggest that elevated MCP-1 might act as a signal for inflammatory cells to infiltrate the kidney in lupus nephritis...
  51. ncbi Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heymann nephritis
    A Remuzzi
    Department of Kidney Research, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Lab Invest 79:1501-10. 1999
    ..These selective effects on glomerular podocytes may contribute to preserve water and macromolecule permeability of the glomerular capillary wall in this immunologic model of kidney disease...
  52. ncbi Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial
    E Gotti
    Negri Bergamo Labs, Mario Negri Institute for Pharmacological Research, Via Gavazzeni II, Bergamo 24125, Italy
    Transplant Proc 37:2037-40. 2005
    ..These findings underline the need to target cyclosporine therapy early posttransplant to modulate T-cell activation...
  53. ncbi How renal cytokines and growth factors contribute to renal disease progression
    A Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Kidney Dis 37:S21-4. 2001
    ..Limiting protein traffic and the biological effect of excessive tubular protein reabsorption by drugs interfering with AII synthesis or biological activity prevents renal disease progression...
  54. ncbi Co-participation of thromboxane A2 and leukotriene C4 and D4 in mediating cyclosporine-induced acute renal failure
    N Perico
    Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Italy
    Transplantation 52:873-8. 1991
    ..80 +/- 0.09 ml/min/100 g body wt) and RPF (2.40 +/- 0.12 ml/min/100 g body wt). These findings suggest that TxA2 and LTC4/LTD4 participate in mediating renal function deterioration induced by acute CsA administration in the rat...
  55. ncbi Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies
    P Ruggenenti
    , Mario Negri Institute for Pharmacological Research, and Unit of Nephrology, Ospedali Riuniti, Azienda Ospedaliera, Bergamo, Italy
    Kidney Int 59:286-94. 2001
    ..CONCLUSIONS: In our study population, ramipril prolongs life while saving money because of its beneficial effect on the course of nondiabetic chronic nephropathies...
  56. ncbi 17beta-estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases
    M Noris
    Mario Negri Institute for Pharmacological Research, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, 24125 Bergamo, Italy
    Am J Physiol Renal Physiol 279:F626-35. 2000
    ..These results provide a possible biochemical explanation of the well-known effect of estrogens on primary hemostasis in uremia, in experimental animals and humans...
  57. ncbi ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy
    P Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Dacco Villa Camozzi, Ranica, Italy
    J Am Soc Nephrol 12:2832-7. 2001
    ..However, renoprotection is maximized when ACE inhibition is started earlier and when long-lasting treatment may result in GFR stabilization and definitive prevention of ESRD...
  58. ncbi Renoprotective therapy in patients with nondiabetic nephropathies
    R Pisoni
    Department of Kidney Research, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Drugs 61:733-45. 2001
    ....
  59. ncbi Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation
    C Zoja
    Mario Negri Institute for Pharmacological Research, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Italy
    Kidney Int 53:1608-15. 1998
    ..Given its chemotactic activity, RANTES released into the interstitium might promote inflammatory cell recruitment and contribute to interstitial inflammation and renal disease progression...
  60. ncbi Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients
    R Caruso
    Department of Immunology and Clinics of Organ Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Clin Chem 47:1679-87. 2001
    ..Moreover, a single CN activity monitoring at baseline or at time 12 h post-CsA dosing may be a useful surrogate for the inhibition of this enzyme by CsA during 12 h...
  61. ncbi Thrice-weekly in-center nocturnal hemodialysis: an effective strategy to optimize chronic dialysis therapy
    P Cravedi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Int J Artif Organs 32:12-9. 2009
    ..Thrice NHD might represent a more affordable approach to improve hemodialysis patient outcome...
  62. ncbi Nephrotoxic aspects of cyclosporine
    D Cattaneo
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplant Proc 36:234S-239S. 2004
    ....
  63. ncbi Peripheral donor leukocytes prolong survival of rat renal allografts
    M Noris
    Department of Immunology and Clinics of Organ Transplantation, Ospedali Riuniti Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 56:1101-12. 1999
    ..The development of strategies to enhance the survival of transplanted organs and to potentially lower or even discontinue immunosuppressive therapy would represent a significant advancement in post-transplant patient care...
  64. ncbi Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial
    Giuseppe Remuzzi
    Department of Renal Medicine, Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 18:1973-85. 2007
    ..In view of the cost, standard immunosuppression regimens for kidney transplantation should perhaps include azathioprine rather than MMF...
  65. ncbi The RAAS in the pathogenesis and treatment of diabetic nephropathy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Nat Rev Nephrol 6:319-30. 2010
    ..Such findings will have major implications, particularly in settings where money and facilities are limited and in settings where renal replacement therapy is not available and the prevention of kidney failure is life saving...
  66. ncbi Does remission of renal disease associated with antihypertensive treatment exist?
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, Bergamo, Italy
    Curr Hypertens Rep 9:160-5. 2007
    ..Early intervention, before progressive glomerulosclerosis and scarring is initiated by increased protein traffic, may be important to maximize reno- and cardioprotection, especially in diabetes...
  67. ncbi Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses
    Carlos Chiurchiu
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 16:S58-63. 2005
    ..The meta-analyses, however, represent a valuable tool to evaluate the consistency and generalizability of trial results to larger cohorts of patients...
  68. ncbi Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients
    D Cattaneo
    Department of Immunology and Clinics of Organ Transplantation, Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Clin Transplant 15:402-9. 2001
    ..However, no correlation has been shown between fixed MMF dose and clinical outcome...
  69. ncbi Erythropoietin enhances immunostimulatory properties of immature dendritic cells
    F Rocchetta
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin Exp Immunol 165:202-10. 2011
    ..It is tempting to speculate that EPO could act as an additional danger signal in concert with TLR-4 engagement. Thus, EPO, beyond its erythropoietic and cytoprotective effects, turns out to be an immune modulator...
  70. ncbi Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress
    M Morigi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Blood 98:1828-35. 2001
    ..These results might help to explain why thrombi in HUS localize in microvessels rather than in larger ones and provide insights on the molecular events involved in the process of microvascular thrombosis associated with D+HUS...
  71. ncbi ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease
    A Remuzzi
    Department of Biomedical Engineering, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 69:1124-30. 2006
    ..Hence, ACE inhibition, which is widely used in human kidney disease, may not only halt the progression of renal failure, but also actually induce the regeneration of new renal tissue...
  72. ncbi Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice
    P Trionfini
    Department of Molecular Medicine, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Gene Ther 16:1373-9. 2009
    ..The secreted ADAMTS13 protein was functionally active even after 2 months from injection. The data provide the proof of principle for developing a novel therapy for the correction of ADAMTS13 deficiency in patients with hereditary TTP...
  73. ncbi Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination
    Sanjib Kumar Sharma
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy
    Vasc Health Risk Manag 3:453-65. 2007
    ..Thus, trandolapril/verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure...
  74. ncbi Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model
    Borislav D Dimitrov
    Clinical Research Center for Rare Diseases Aldo e Cele Dacc, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Nephron Clin Pract 95:c47-59. 2003
    ..This may help in optimizing care and costs in nephrology and other medical areas and designing trials in high-risk patients...
  75. ncbi Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies
    Ruth Campbell
    Clinical Research Center for Rare Diseases Aldo and Cele Dacc, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 63:1094-103. 2003
    ..Long-term combined ACEi and ARA therapy may be more renoprotective than treatment with each agent alone...
  76. ncbi Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade
    Aneliya Parvanova
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacc, Villa Camozzi, Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Expert Opin Pharmacother 6:1931-42. 2005
    ..Whether this also applies to diabetic nephropathy and related cardiovascular outcomes is still unknown...
  77. ncbi Proteinuria in diabetic nephropathy: treatment and evolution
    Ruth C Campbell
    Division of Nephrology and Dialysis, Ospedali Riuniti di Bergamo and Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11, Bergamo 24125, Italy
    Curr Diab Rep 3:497-504. 2003
    ..Screening and implementation of these strategies is needed to reverse the epidemic of diabetic renal disease...
  78. ncbi Intensified inhibition of renin-angiotensin system: a way to improve renal protection?
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11 24125 Bergamo, Italy
    Curr Hypertens Rep 9:430-6. 2007
    ....
  79. ncbi Proteinuria and its consequences in renal disease
    A Schieppati
    Clinical Research Centre for Rare Diseases, Aldo e Cele Dacc, Ranica, Italy
    Acta Paediatr Suppl 92:9-13; discussion 5. 2003
    ..CONCLUSION: A range of therapeutic options, used in conjunction with enzyme replacement therapy, may have beneficial effects on the renal manifestations of Fabry disease...
  80. ncbi Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results
    Giuseppe Remuzzi
    Clinical Research Center for Rare Diseases Aldo e Cele Dacc, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 15:3117-25. 2004
    ..Angiotensin II antagonism is a suitable and well-tolerated treatment for individuals with type 2 diabetes even with GFR levels approaching renal replacement therapy...
  81. ncbi Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion
    Aneliya I Parvanova
    Aldo e Cele Dacco Clinical Research Centre for Rare Diseases, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, 24125 Bergamo, Italy
    Diabetes 55:1456-62. 2006
    ..Longitudinal studies are needed to clarify the role of insulin resistance in the pathogenesis of microalbuminuria and related complications...
  82. ncbi Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy
    Clin J Am Soc Nephrol 3:1511-25. 2008
    ....
  83. ncbi Rituximab in idiopathic membranous nephropathy: a one-year prospective study
    Piero Ruggenenti
    , Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 14:1851-7. 2003
    ..The long-term risk/benefit profile of this novel, disease-specific approach seems much more favorable to that of commonly employed immunosuppressive drugs...
  84. ncbi The diabetic CKD patient--a major cardiovascular challenge
    Irene M van der Meer
    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Ren Care 36:34-46. 2010
    ..Those involved in the delivery of care to patients with diabetes and CKD need to be aware of these issues and should adopt an individualised approach to treatment...
  85. ncbi Sirolimus therapy to halt the progression of ADPKD
    Norberto Perico
    Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 21:1031-40. 2010
    ..In summary, sirolimus halted cyst growth and increased parenchymal volume in patients with ADPKD. Whether these effects translate into improved long-term outcomes requires further investigation...
  86. ncbi The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20
    J Caprioli
    Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 12:297-307. 2001
    ..The mutations identified here give an important hint to the relevance of the C-terminus of factor H in the control of the alternative complement activation pathway...
  87. ncbi One or two marginal organs for kidney transplantation?
    N Perico
    Department of Medicine and Transplantation, Ospedali Riuniti Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplant Proc 34:3091-6. 2002
  88. ncbi Post-transplant renal artery stenosis: the hemodynamic response to revascularization
    P Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, and Units of Nephrology and Radiology, Ospedali Riuniti, Azienda Ospedaliera, Bergamo, Italy
    Kidney Int 60:309-18. 2001
    ..However, the real impact of this procedure on renal function recovery has never been quantitated precisely to date...
  89. ncbi Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease
    C Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 70:97-103. 2006
    ....
  90. ncbi Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats
    M Figliuzzi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplant Proc 41:1797-800. 2009
    ..In conclusion, our study indicated that co-transplantation of MSCs with pancreatic islets improved islet graft function by promoting graft vascularization...
  91. ncbi Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats
    D Macconi
    Department of Kidney Research, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 11:477-89. 2000
    ....
  92. ncbi Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis
    M Noris
    Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Villa Camozzi Ranica BG, Italy
    Clin Exp Immunol 151:199-209. 2008
    ..The new genetic and pathogenetic findings in these diseases and their clinical implications for the management and cure of patients are reviewed in this paper...
  93. ncbi Thrombotic microangiopathy after kidney transplantation
    M Noris
    Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy
    Am J Transplant 10:1517-23. 2010
    ..Prophylactic and therapeutic options for posttransplant TMA, including plasma therapy, combined kidney and liver transplantation and targeted complement inhibitors are discussed in this review...
  94. ncbi Which antihypertensive drugs are the most nephroprotective and why?
    Paolo Cravedi
    Mario Negri Institute of Pharmacological Research, Parco Scientifico Tecnologico Kilometro Rosso, Department of Medicine and Transplantation, Via Stezzano, 87, Ospedali Riuniti, 24126 Bergamo, Italy
    Expert Opin Pharmacother 11:2651-63. 2010
    ..Choice of antihypertensive strategies with highest nephroprotective effect is crucial to prevent or reverse progression to end stage renal disease (ESRD)...
  95. ncbi Overview of randomised trials of ACE inhibitors
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research and Unit of Nephrology and Dialysis, Ospedali Riuniti, Bergamo 24125, Italy
    Lancet 368:555-6. 2006
  96. ncbi Successes and disappointments with clinical islet transplantation
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, 24125, Bergamo, Italy
    Adv Exp Med Biol 654:749-69. 2010
    ..At present, pancreatic islet transplantation is still an experimental procedure, which is only indicated for a highly selected group of type 1 diabetic patients with life-threatening hypoglycaemic episodes...
  97. ncbi Latest treatment strategies for membranous nephropathy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Department of Renal Medicine, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Via Gavazzeni 11, 24125 Bergamo, Italy
    Expert Opin Pharmacother 8:3159-71. 2007
    ..This paper reviews the safety/efficacy profile of various agents that have been proposed as therapy for this disease, with particular focus on the latest, more specific and hypothesis-driven approaches...
  98. ncbi Developing regulatory-compliant electronic case report forms for clinical trials: experience with the demand trial
    Bogdan Ene-Iordache
    Laboratory of Biomedical Technologies, Clinical Research Center for Rare Diseases Aldo e Cele Dacò, Via G B Camozzi 3, 24020 Ranica BG, Italy
    J Am Med Inform Assoc 16:404-8. 2009
    ..Here the authors focus on the development of computerized systems for clinical trials implementing FDA and EU recommendations and regulations, and describe a laptop-based electronic CRF used in a randomized, multicenter clinical trial...
  99. ncbi Rituximab for idiopathic membranous nephropathy
    Giuseppe Remuzzi
    Ospedali Riuniti Di Bergam, Unit of Nephrology and Dialysis, Aldo and Cele Daccò Clinical Research Centre for Diseases, Mario Negri Institute for Parmacological Research, Via Gavazzeni 1124125, Bergamo, Italy
    Lancet 360:923-4. 2002
    ..CD20 B lymphocytes fell below normal ranges up to study end. The short-term risk-benefit profile of rituximab seems more favourable to that of any other immunosuppressive drug used to treat idiopathic membranous nephropathy...
  100. ncbi Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury
    Piero Ruggenenti
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Bergamo, Italy
    Transplantation 84:956-64. 2007
    ..This might translate into more effective protection against chronic graft injury compared to cyclosporin A (CsA), which, in the same clinical setting, does not affect Treg...
  101. ncbi Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study
    Giuseppe Remuzzi
    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 17:S90-7. 2006
    ..The apparent advantage of ACE inhibitors over other agents includes a protective effect on the kidney against the development of microalbuminuria, which is a major risk factor for cardiovascular events and death in this population...